Loading…
Biotech developing furmonertinib, an EGFR-targeted lung-cancer drug in-licensed from a Chinese partner, for global markets.
Biotech developing furmonertinib, an EGFR-targeted lung-cancer drug in-licensed from a Chinese partner, for global markets.
Pre-revenue: it sells nothing and pays for trials from cash raised in its early-2024 listing and other share sales. Rights to furmonertinib outside Greater China come from Shanghai Allist, which sells it in China, so any US approval would bring milestone and royalty payments to Allist.
Moat: narrow (IP / patents). Exclusive ex-China rights to a differentiated EGFR inhibitor already approved in China.
Headquarters: Newtown Square, Pennsylvania, US · Founded: 2021 · Employees: 77
Size ArriVent BioPharma (AVBP) is a United States Health Care company (Pharmaceuticals: Other) with a market value of $673M, the 2514th largest of 3,117 United States companies the cockpit tracks. Shares closed at $13.64 on 6 Nov 2026.
Performance Over six months the shares fell 53.8%, against -17.2% for the median peer and -1.1% for the United States market (cap-weighted) — lowest of 21 in its peer set.
Short interest Short interest is 13.8% of the free float (15 Oct 2026).
Next results Next results expected around 18 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | $0 | $0 | $0 | $0 | $0 |
| EBITDA | -$176M | -$178M | -$94.3M | -$74.6M | -$36.9M |
| Net income | -$164M | -$166M | -$80.5M | -$69.3M | -$36.9M |
| Free cash flow | -$148M | -$161M | -$70.2M | -$55.8M | -$43.6M |
| Capital expenditure | $0 | $0 | $0 | $0 | $0 |
| Total debt | $351,000 | $14,000 | $176,000 | $317,000 | $139,000 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| ArriVent BioPharma AVBP | $673M | -54% | n/a | n/a | n/a | n/a |
| AstraZeneca AZN.L | $291B | +1% | +5% | 23% | 5.1× | 14.5% |
| Johnson & Johnson JNJ | $665B | +26% | +8% | 26% | 7.0× | 3.5% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | AVBP | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -18.4% | -7.1% | 2nd lowest of 21 |
| 6-month return | -53.8% | -17.2% | lowest of 21 |
| Distance from 52-week high | -61.9% | -35.7% | lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| ArriVent BioPharma AVBP | United States | $673M | -54% | n/a | n/a | n/a | n/a | n/a |
| CK Life Sciences International (Holdings) 0775.HK | Hong Kong | $644M | -30% | 0% | 0% | 2.1× | n/a | n/a |
| ABA Chemicals 300261.SZ | China | $641M | -27% | -16% | -23% | 5.2× | n/a | n/a |
| Shanxi Zhendong Pharmaceutical 300158.SZ | China | $713M | -16% | -28% | -25% | 2.0× | n/a | n/a |
| Brother Enterprises 002562.SZ | China | $716M | -28% | +8% | 4% | 1.6× | 4.9% | +13.5% |
| China Shineway Pharmaceutical 2877.HK | Hong Kong | $719M | -21% | -18% | 25% | n/a | n/a | n/a |
| Hangzhou Minsheng Healthcare 301507.SZ | China | $624M | -21% | +21% | 11% | 4.1× | 20.4% | +12.1% |
| Shanghai Kaibao Pharmaceutical 300039.SZ | China | $756M | -17% | -14% | 22% | 3.7× | 1.8% | +4.8% |
| Lanzhou Foci Pharmaceutical 002644.SZ | China | $582M | -9% | +3% | 5% | 3.6× | 24.3% | +6.5% |
| Hunan Hansen Pharmaceutical 002412.SZ | China | $582M | +10% | -4% | 21% | 3.4× | 3.0% | +7.0% |
| Lionco Pharmaceutical 603669.SS | China | $581M | +21% | -6% | -17% | 10.2× | n/a | n/a |
| Sirio Pharma 300791.SZ | China | $790M | -12% | -9% | 1% | 1.6× | 14.7% | +15.6% |
| Tianjin Tianyao Pharmaceuticals 600488.SS | China | $801M | -14% | -12% | 3% | 2.5× | 3.6% | -1.3% |
| PharmaNutra PHN.MI | Italy | $808M | -18% | +18% | 21% | 5.1× | 4.0% | +18.5% |
| TSI 603262.SS | China | $909M | -41% | +3% | 14% | 5.0× | 25.8% | +13.4% |
| Sihuan Pharmaceutical 0460.HK | Hong Kong | $952M | -35% | +30% | 15% | 2.3× | n/a | n/a |
| Myung in Pharm 317450.KS | South Korea | $455M | -24% | +7% | 35% | 2.1× | -14.7% | +8.9% |
| New Journey Health Technology Group Co., Ltd.Class A 002219.SZ | China | $999M | -16% | -14% | 8% | 3.0× | n/a | n/a |
| Applied Nutrition APN.L | United Kingdom | $1.01B | +42% | +24% | n/a | n/a | n/a | n/a |
| Tibet Aim Pharm 002826.SZ | China | $427M | -23% | +13% | 14% | 3.1× | 1.3% | +1.0% |
| Shandong Xinhua Pharmaceutical 000756.SZ | China | $1.09B | -10% | -5% | 4% | 1.0× | 1.5% | +7.9% |